Abstract
Bronchial asthma is a serious problem of pediatric pulmonology. The vasoactive intestinal peptide (VIP) plays an important role in the pathogenesis of bronchial obstruction during the period of exacerbation of the disease. Therefore, the concentration of VIP in the serum of children with asthma has important clinical significance. Objective: to evaluate the role of VIP in the pathogenesis of bronchial obstruction in children with asthma. Materials and methods: 30 patients (aged 5 to 18 years) with asthma were examined. The control group consisted of 30 children. All patients underwent a comprehensive clinical examination. The content of VIP in blood plasma were determined using the test system EIA for VIP Penisula Laboratories, USA. Results: It was found that the concentration of VIP in the serum at patients with asthma in the period of exacerbation of the disease (110,60±11,89 nmol/l) significantly higher than children in the control group (53,26±16,08 nmol/l) [p=0,016]. Moreover, the concentration of VIP in serum increased depending on the severity of asthma: concentration of VIP in the blood in patients with a light attack of asthma was 88,81±31,14 nmol/l, with moderate - 100,27±16,27 nmol/l, severe - 107,34±22,70 nmol/L. Taking into account the fact that VIP has endogenous bronchodilator action, it can be assumed that the increase of its concentration indicates of mobilization of body defenses aimed at relief of bronchial obstruction in children with asthma. Conclusion: the increased concentration of VIP in the serum of children with asthma indicates the activation of protective mechanisms in the period of exacerbation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
